LABELS · 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
OPDIVO QVANTIG
Open original source → · Download preserved record
Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.
- Label effective date
- 2026-05-12
- Captured
- 2026-09-09T23:37:39.774134+00:00
- Current indication reconciliation
- Not reconciled
Indications and usage: exact source text
- 1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.1) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. (1.1) • adult patients with advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma. (1.2) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab. (1.2) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.3) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.4) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery. (1.5) • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. (1.6) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy. (1.7) Urothelial Carcinoma (UC) • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC. (1.8) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.8) • adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.8) Colorectal Cancer (CRC) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), following combination treatment with intravenous nivolumab and ipilimumab. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • adult patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic HCC. Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.11) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1). (1.11) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. (1.11) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.12) 1.1 Advanced Renal Cell Carcinoma OPDIVO QVANTIG™, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab combination therapy. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. OPDIVO QVANTIG, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic therapy. 1.2 Unresectable or Metastatic Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma following treatment with intravenous nivolumab and ipilimumab combination therapy. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. 1.3 Adjuvant Treatment of Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. 1.4 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC). 1.5 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by OPDIVO QVANTIG as monotherapy in the adjuvant setting after surgical resection. 1.6 Metastatic Non-Small Cell Lung Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. 1.7 Squamous Cell Carcinoma of the Head and Neck OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy. 1.8 Urothelial Carcinoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. OPDIVO QVANTIG, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic UC. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 1.9 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) following treatment with intravenous nivolumab and ipilimumab combination therapy. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater, with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. 1.10 Hepatocellular Carcinoma • OPDIVO QVANTIG, as monotherapy, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following treatment with intravenous nivolumab and ipilimumab combination therapy. • OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafenib following treatment with intravenous nivolumab and ipilimumab combination therapy . Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable or metastatic HCC. 1.11 Esophageal Cancer OPDIVO QVANTIG as monotherapy, is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT). OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] . Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. OPDIVO QVANTIG as monotherapy, is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. 1.12 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] .
Full extracted label fields
- application numbers
- BLA761381
- boxed warning exact
- brand names
- OPDIVO QVANTIG
- current indication status
- not_reconciled
- dailymed set url
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- indications and usage exact
- 1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.1) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. (1.1) • adult patients with advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma. (1.2) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab. (1.2) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.3) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.4) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery. (1.5) • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. (1.6) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy. (1.7) Urothelial Carcinoma (UC) • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC. (1.8) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.8) • adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.8) Colorectal Cancer (CRC) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), following combination treatment with intravenous nivolumab and ipilimumab. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • adult patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic HCC. Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.11) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1). (1.11) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. (1.11) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.12) 1.1 Advanced Renal Cell Carcinoma OPDIVO QVANTIG™, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab combination therapy. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. OPDIVO QVANTIG, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic therapy. 1.2 Unresectable or Metastatic Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma following treatment with intravenous nivolumab and ipilimumab combination therapy. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. 1.3 Adjuvant Treatment of Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. 1.4 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC). 1.5 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by OPDIVO QVANTIG as monotherapy in the adjuvant setting after surgical resection. 1.6 Metastatic Non-Small Cell Lung Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. 1.7 Squamous Cell Carcinoma of the Head and Neck OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy. 1.8 Urothelial Carcinoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. OPDIVO QVANTIG, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic UC. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 1.9 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) following treatment with intravenous nivolumab and ipilimumab combination therapy. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater, with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. 1.10 Hepatocellular Carcinoma • OPDIVO QVANTIG, as monotherapy, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following treatment with intravenous nivolumab and ipilimumab combination therapy. • OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafenib following treatment with intravenous nivolumab and ipilimumab combination therapy . Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable or metastatic HCC. 1.11 Esophageal Cancer OPDIVO QVANTIG as monotherapy, is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT). OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] . Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. OPDIVO QVANTIG as monotherapy, is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. 1.12 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] .
- indications and usage tables exact
- is original packager
- true
- manufacturer names
- E.R. Squibb & Sons, L.L.C.
- matched search terms
- cancer
- carcinoma
- lymphoma
- melanoma
- tumor
- tumors
- package ndcs
- 0003-6120-01
- 0003-3120-01
- product ndcs
- 0003-3120
- 0003-6120
- product types
- HUMAN PRESCRIPTION DRUG
- recent major changes exact
- Indications and Usage (1) 11/2025 Dosage and Administration (2) 11/2025 Warnings and Precautions (5) 5/2026
- record type
- complete_spl_indications_section_candidate
- routes
- SUBCUTANEOUS
- rxcuis
- 2700798
- 2700805
- 2728491
- 2728492
- source batch
- file
- /private/tmp/cancer-full-research/indications/raw/labels-00000.json
- meta
- disclaimer
- Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
- last updated
- 2026-09-09
- results
- limit
- 100
- skip
- 0
- total
- 830
- sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl effective time
- 20260512
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- substance names
- NIVOLUMAB
- HYALURONIDASE (HUMAN RECOMBINANT)
- uniis
- 743QUY4VD8
- 31YO63LBSN
- verification flags
- oncology_keyword_candidate_not_clinically_classified
- spl_text_not_verified_identical_to_latest_approved_label
- individual_indications_not_split_or_reconciled
- fda_label_posted_after_spl_effective_date_requires_version_review
Drugs@FDA application source records
- application number
- BLA761381
- payload
- all indexed label documents
- Appl No
- 761381
- Application Docs Date
- 2025-06-13 00:00:00
- Application Docs ID
- 80780
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761381Orig1s000correctedlbl.pdf
- Submission No
- 1
- Submission Type
- ORIG
- Appl No
- 761381
- Application Docs Date
- 2025-06-02 00:00:00
- Application Docs ID
- 82399
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761381s008lbl.pdf
- Submission No
- 8
- Submission Type
- SUPPL
- Appl No
- 761381
- Application Docs Date
- 2025-10-28 00:00:00
- Application Docs ID
- 83941
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761381s001lbl.pdf
- Submission No
- 1
- Submission Type
- SUPPL
- Appl No
- 761381
- Application Docs Date
- 2025-10-28 00:00:00
- Application Docs ID
- 83942
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761381s002lbl.pdf
- Submission No
- 2
- Submission Type
- SUPPL
- Appl No
- 761381
- Application Docs Date
- 2025-11-25 00:00:00
- Application Docs ID
- 84312
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761381s005lbl.pdf
- Submission No
- 5
- Submission Type
- SUPPL
- Appl No
- 761381
- Application Docs Date
- 2026-05-18 00:00:00
- Application Docs ID
- 85949
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761381s012lbl.pdf
- Submission No
- 12
- Submission Type
- SUPPL
- Appl No
- 761381
- Application Docs Date
- 2026-05-18 00:00:00
- Application Docs ID
- 85950
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761381s012lbl.pdf
- Submission No
- 12
- Submission Type
- SUPPL
- all submission records
- Appl No
- 761381
- Review Priority
- STANDARD
- Submission Class Code ID
- 12
- Submission No
- 1
- Submission Status
- AP
- Submission Status Date
- 2024-12-27 00:00:00
- Submission Type
- ORIG
- Submissions Public Notes
- Appl No
- 761381
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 1
- Submission Status
- AP
- Submission Status Date
- 2025-10-27 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761381
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 2
- Submission Status
- AP
- Submission Status Date
- 2025-10-27 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761381
- Review Priority
- STANDARD
- Submission Class Code ID
- 2
- Submission No
- 5
- Submission Status
- AP
- Submission Status Date
- 2025-11-24 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761381
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 8
- Submission Status
- AP
- Submission Status Date
- 2025-05-23 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- Appl No
- 761381
- Review Priority
- STANDARD
- Submission Class Code ID
- 3
- Submission No
- 12
- Submission Status
- AP
- Submission Status Date
- 2026-05-12 00:00:00
- Submission Type
- SUPPL
- Submissions Public Notes
- application number
- BLA761381
- approval interpretation
- Application linkage and approved submission are not indication-level current approval verification
- current indication status
- not_reconciled
- drugsfda url
- https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761381
- has approved submission record
- true
- latest approved submission date
- 2026-05-12
- latest label selection rule
- max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
- latest posted label documents
- Appl No
- 761381
- Application Docs Date
- 2026-05-18 00:00:00
- Application Docs ID
- 85949
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761381s012lbl.pdf
- Submission No
- 12
- Submission Type
- SUPPL
- Appl No
- 761381
- Application Docs Date
- 2026-05-18 00:00:00
- Application Docs ID
- 85950
- Application Docs Title
- 0
- Application Docs Type ID
- 2
- Application Docs URL
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761381s012lbl.pdf
- Submission No
- 12
- Submission Type
- SUPPL
- official application record
- Appl No
- 761381
- Appl Public Notes
- Appl Type
- BLA
- Sponsor Name
- BRISTOL-MYERS SQUIBB
- openfda application present
- true
- products
- Active Ingredient
- NIVOLUMAB;HYALURONIDASE-NVHY
- Appl No
- 761381
- Drug Name
- OPDIVO QVANTIG
- Form
- INJECTABLE;SUBCUTANEOUS
- Product No
- 001
- Reference Drug
- 0
- Reference Standard
- 0
- Strength
- 600MG;10000UNITS PER5ML(120MG/2000UNITS PER ML)
- marketing status
- Prescription
Source passages and status connections
Passage 1 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 423
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.1) • Limitations of Use: OPDIVO Q
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 0
- current approval status
- not_reconciled
- duplicate text group
- dup-20e52d37e7826b142d93
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-51c3e38e9359259290d8
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 178
- end exclusive
- true
- exact text
- indicated for
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 165
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 223
- end exclusive
- true
- exact text
- 1 INDICATIONS AND USAGE OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 0
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 2 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- inherited_predicate_from_same_label_section_requires_review
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 586
- end exclusive
- true
- exact text
- OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.1) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 24
- current approval status
- not_reconciled
- duplicate text group
- dup-b3c910d957665a1703da
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-fd76d1c66fab77a4098c
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 178
- end exclusive
- true
- exact text
- indicated for
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 165
- qualifier mentions
- context exact
- • adult patients with intermediate or poor risk advanced RCC, as a first-lin
- kind
- age
- polarity
- not_inferred
- span
- end
- 240
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 226
- context exact
- • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 284
- end exclusive
- true
- exact text
- advanced RCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 272
- context exact
- patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 385
- end exclusive
- true
- exact text
- first-line treatment following combination treatment with intravenous nivolumab and ipilimumab
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 291
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 386
- end exclusive
- true
- exact text
- • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 224
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 3 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 592
- end exclusive
- true
- exact text
- tment of: Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.1) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combin
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 187
- current approval status
- not_reconciled
- duplicate text group
- dup-c50dfa03542198e71aa7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-acb7a61be6f51c5296a7
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 392
- end exclusive
- true
- exact text
- (1.1)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 387
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 4 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 720
- end exclusive
- true
- exact text
- of: Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.1) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. (1.1) • adult patients with advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melan
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 193
- current approval status
- not_reconciled
- duplicate text group
- dup-d87ddbb0655b518e27e3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-49b78ea3eb243b1d7303
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 519
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of renal cell carcinoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 447
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 520
- end exclusive
- true
- exact text
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 393
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 5 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 816
- end exclusive
- true
- exact text
- combination treatment with intravenous nivolumab and ipilimumab. (1.1) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. (1.1) • adult patients with advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresect
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 321
- current approval status
- not_reconciled
- duplicate text group
- dup-766d434bfb945059fd8b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-d28fc6cedaf2cae846bf
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with advanced RCC, as a first-line treatment in combination
- kind
- age
- polarity
- not_inferred
- span
- end
- 537
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 523
- context exact
- • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 555
- end exclusive
- true
- exact text
- advanced RCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 543
- context exact
- • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 615
- end exclusive
- true
- exact text
- first-line treatment in combination with cabozantinib
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 562
- context exact
- adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 615
- end exclusive
- true
- exact text
- in combination with cabozantinib
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 583
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 616
- end exclusive
- true
- exact text
- • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 521
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 6 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 822
- end exclusive
- true
- exact text
- DIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. (1.1) • adult patients with advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable o
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 417
- current approval status
- not_reconciled
- duplicate text group
- dup-c50dfa03542198e71aa7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-3c070d4537b33d567bce
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 622
- end exclusive
- true
- exact text
- (1.1)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 617
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 7 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 906
- end exclusive
- true
- exact text
- VANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. (1.1) • adult patients with advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma. (1.2) • adult and pediatric (12 years and older who weigh 30
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 423
- current approval status
- not_reconciled
- duplicate text group
- dup-2c8068074819ce390aef
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-39b7b11cc84806a21a86
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with advanced RCC who have received prior anti-angiogenic t
- kind
- age
- polarity
- not_inferred
- span
- end
- 639
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 625
- context exact
- • adult patients with advanced RCC who have received prior anti-angiogenic therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 688
- end exclusive
- true
- exact text
- advanced RCC who have received prior anti-a
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 645
- context exact
- • adult patients with advanced RCC who have received prior anti-angiogenic therapy.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 705
- end exclusive
- true
- exact text
- who have received prior anti-angiogenic therapy
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 658
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 706
- end exclusive
- true
- exact text
- • adult patients with advanced RCC who have received prior anti-angiogenic therapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 623
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 8 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 923
- end exclusive
- true
- exact text
- ll carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. (1.1) • adult patients with advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma. (1.2) • adult and pediatric (12 years and older who weigh 30 kg or greater) pa
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 507
- current approval status
- not_reconciled
- duplicate text group
- dup-e540e99c2b05b1565735
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-339321a26ad0451bdf0f
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 723
- end exclusive
- true
- exact text
- ( 1.1 ) Melanoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 707
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 9 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1044
- end exclusive
- true
- exact text
- dult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. (1.1) • adult patients with advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma. (1.2) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 524
- current approval status
- not_reconciled
- duplicate text group
- dup-c2f3101ebc936b73acd2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-fe378ec444f67cd41ef8
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult and pediatric (12 years and older who weigh 30 kg or greate
- kind
- age
- polarity
- not_inferred
- span
- end
- 731
- end exclusive
- true
- exact text
- adult
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 726
- context exact
- • adult and pediatric (12 years and older who weigh 30 kg or greater) patients wi
- kind
- age
- polarity
- not_inferred
- span
- end
- 745
- end exclusive
- true
- exact text
- pediatric
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 736
- context exact
- • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or m
- kind
- age
- polarity
- not_inferred
- span
- end
- 765
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 747
- context exact
- r who weigh 30 kg or greater) patients with unresectable or metastatic melanoma.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 843
- end exclusive
- true
- exact text
- metastatic melanoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 824
- context exact
- 2 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 843
- end exclusive
- true
- exact text
- unresectable or metastatic melanoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 808
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 844
- end exclusive
- true
- exact text
- • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 724
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 10 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1050
- end exclusive
- true
- exact text
- advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma. (1.2) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab. (1.2
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 645
- current approval status
- not_reconciled
- duplicate text group
- dup-8a37bc926471f986741f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-17d6786b38c95f5fabc1
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 850
- end exclusive
- true
- exact text
- (1.2)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 845
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 11 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1245
- end exclusive
- true
- exact text
- ed RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma. (1.2) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab. (1.2) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. • for the adjuvant treatment of adult and pediatri
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 651
- current approval status
- not_reconciled
- duplicate text group
- dup-8bc833bc71f18462f1f7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-3f6f88393bac4e0b0ee5
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult and pediatric (12 years and older who weigh 30 kg or greate
- kind
- age
- polarity
- not_inferred
- span
- end
- 858
- end exclusive
- true
- exact text
- adult
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 853
- context exact
- • adult and pediatric (12 years and older who weigh 30 kg or greater) patients wi
- kind
- age
- polarity
- not_inferred
- span
- end
- 872
- end exclusive
- true
- exact text
- pediatric
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 863
- context exact
- • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or m
- kind
- age
- polarity
- not_inferred
- span
- end
- 892
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 874
- context exact
- r who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 994
- end exclusive
- true
- exact text
- metastatic melanoma following combination t
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 951
- context exact
- 2 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimum
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 982
- end exclusive
- true
- exact text
- unresectable or metastatic melanoma following c
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 935
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 1045
- end exclusive
- true
- exact text
- • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 851
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 12 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1251
- end exclusive
- true
- exact text
- 1.2) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab. (1.2) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. • for the adjuvant treatment of adult and pediatric (12
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 846
- current approval status
- not_reconciled
- duplicate text group
- dup-8a37bc926471f986741f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-a6a9ec4a97ccf0e78479
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 1051
- end exclusive
- true
- exact text
- (1.2)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1046
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 13 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 1394
- end exclusive
- true
- exact text
- adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab. (1.2) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.3) Non-
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 852
- current approval status
- not_reconciled
- duplicate text group
- dup-5c506ca5c80f49026c53
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-eb10c83868cf359ba76b
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- nation with ipilimumab for the treatment of unresectable or metastatic melanoma.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1193
- end exclusive
- true
- exact text
- metastatic melanoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1174
- context exact
- dicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1193
- end exclusive
- true
- exact text
- unresectable or metastatic melanoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1158
- context exact
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1193
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of unresectable or metastatic melanoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1106
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 1194
- end exclusive
- true
- exact text
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1052
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 14 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1583
- end exclusive
- true
- exact text
- eatment with intravenous nivolumab and ipilimumab. (1.2) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.3) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.4) •
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 995
- current approval status
- not_reconciled
- duplicate text group
- dup-b3f49e51bdcd27417ce4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-73cc3f1bb08897e9d42b
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greate
- kind
- age
- polarity
- not_inferred
- span
- end
- 1232
- end exclusive
- true
- exact text
- adult
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1227
- context exact
- • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients wi
- kind
- age
- polarity
- not_inferred
- span
- end
- 1246
- end exclusive
- true
- exact text
- pediatric
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1237
- context exact
- • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resect
- kind
- age
- polarity
- not_inferred
- span
- end
- 1266
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1248
- context exact
- • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1248
- end exclusive
- true
- exact text
- adjuvant treatment of adult and pediatric (
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1205
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 1383
- end exclusive
- true
- exact text
- • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1195
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 15 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1624
- end exclusive
- true
- exact text
- melanoma. • for the adjuvant treatment of adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.3) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.4) • adult patients with resectable (tumors ≥4
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1184
- current approval status
- not_reconciled
- duplicate text group
- dup-a1bdace5439681079466
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-247ed7769c3ea3bb0df5
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 1424
- end exclusive
- true
- exact text
- (1.3) Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1384
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 16 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1774
- end exclusive
- true
- exact text
- f adult and pediatric (12 years and older who weigh 30 kg or greater) patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.3) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.4) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemoth
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1225
- current approval status
- not_reconciled
- duplicate text group
- dup-e37e4f3d430441c595bc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-f0bfb103de4bd0bef0a6
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in th
- kind
- age
- polarity
- not_inferred
- span
- end
- 1441
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1427
- context exact
- • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1492
- end exclusive
- true
- exact text
- resectable (tumors ≥4 cm or node positive) NS
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1447
- context exact
- ith resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1522
- end exclusive
- true
- exact text
- neoadjuvant setting
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1503
- context exact
- s ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1573
- end exclusive
- true
- exact text
- in combination with platinum-doublet chemotherapy
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1524
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 1574
- end exclusive
- true
- exact text
- • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1425
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 17 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 1780
- end exclusive
- true
- exact text
- elanoma. (1.3) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.4) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy,
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1375
- current approval status
- not_reconciled
- duplicate text group
- dup-e3db60e4ebcddab7d85e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-9c04d4d304b8cf387bc2
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 1580
- end exclusive
- true
- exact text
- (1.4)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1575
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 18 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2056
- end exclusive
- true
- exact text
- a. (1.3) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.4) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery. (1.5) • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approv
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1381
- current approval status
- not_reconciled
- duplicate text group
- dup-51d610133b2c628bffda
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-355f6a7d4e6ffafd3962
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and n
- kind
- age
- polarity
- not_inferred
- span
- end
- 1597
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1583
- context exact
- sectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-do
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1701
- end exclusive
- true
- exact text
- EGFR mutations or ALK rearrangements
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1665
- context exact
- • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for n
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1648
- end exclusive
- true
- exact text
- resectable (tumors ≥4 cm or node positive) NS
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1603
- context exact
- SCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followe
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1728
- end exclusive
- true
- exact text
- neoadjuvant treatment
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1707
- context exact
- let chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1855
- end exclusive
- true
- exact text
- adjuvant treatment after surgery
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1823
- context exact
- mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 1855
- end exclusive
- true
- exact text
- in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1730
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 1856
- end exclusive
- true
- exact text
- • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1581
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 19 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2062
- end exclusive
- true
- exact text
- o known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery. (1.5) • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved the
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1657
- current approval status
- not_reconciled
- duplicate text group
- dup-05a3737fdb503132fb5f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-43166fded0141baa1e6f
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 1862
- end exclusive
- true
- exact text
- (1.5)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1857
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 20 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2158
- end exclusive
- true
- exact text
- n EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery. (1.5) • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. (1.6) • Limitations of Use: OPDIVO
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1663
- current approval status
- not_reconciled
- duplicate text group
- dup-b9eae49563dd207d89f8
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-988327dab966deb81b05
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with metastatic NSCLC and progression on or after platinum-
- kind
- age
- polarity
- not_inferred
- span
- end
- 1879
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1865
- context exact
- • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 1928
- end exclusive
- true
- exact text
- metastatic NSCLC and progression on or afte
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1885
- context exact
- • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 1930
- end exclusive
- true
- exact text
- metastatic NSCLC and progression on or after
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1885
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 1958
- end exclusive
- true
- exact text
- • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1863
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 21 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2323
- end exclusive
- true
- exact text
- doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery. (1.5) • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. (1.6) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1759
- current approval status
- not_reconciled
- duplicate text group
- dup-99e1775eef5cf1b0a61a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-eca78f5754dc3e322a9c
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2017
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations should
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1973
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2123
- end exclusive
- true
- exact text
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1959
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 22 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2329
- end exclusive
- true
- exact text
- after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. (1.6) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1924
- current approval status
- not_reconciled
- duplicate text group
- dup-05ad51b27f459de7605d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-8bc1629aef79de2d3322
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2129
- end exclusive
- true
- exact text
- (1.6)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2124
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 23 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 2453
- end exclusive
- true
- exact text
- platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. (1.6) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy. (1.7) Urothelial Carcinoma (UC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1930
- current approval status
- not_reconciled
- duplicate text group
- dup-452be74663a62268b5ca
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-6cd3da7a3a77de210397
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- dicated in combination with ipilimumab for the treatment of metastatic NSCLC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2252
- end exclusive
- true
- exact text
- metastatic NSCLC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2236
- context exact
- dicated in combination with ipilimumab for the treatment of metastatic NSCLC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2252
- end exclusive
- true
- exact text
- metastatic NSCLC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2236
- context exact
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2252
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of metastatic NSCLC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2184
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2253
- end exclusive
- true
- exact text
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2130
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 24 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2506
- end exclusive
- true
- exact text
- oved therapy for these aberrations prior to receiving OPDIVO QVANTIG. (1.6) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy. (1.7) Urothelial Carcinoma (UC) • adjuvant treatment of adult patients with UC who a
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2054
- current approval status
- not_reconciled
- duplicate text group
- dup-bbcd6abc72f1c8a5041e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-9ae59d4cc29530f44070
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2306
- end exclusive
- true
- exact text
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2254
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 25 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2621
- end exclusive
- true
- exact text
- OPDIVO QVANTIG. (1.6) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy. (1.7) Urothelial Carcinoma (UC) • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC. (1.8) • adult patients with unresectable or
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2107
- current approval status
- not_reconciled
- duplicate text group
- dup-a37f7b521f3475690ea3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-371e3de994a14000e2c0
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with recurrent or metastatic SCCHN with disease progression
- kind
- age
- polarity
- not_inferred
- span
- end
- 2323
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2309
- context exact
- • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2385
- end exclusive
- true
- exact text
- metastatic SCCHN with disease progression o
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2342
- context exact
- • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2373
- end exclusive
- true
- exact text
- recurrent or metastatic SCCHN with disease p
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2329
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2421
- end exclusive
- true
- exact text
- • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2307
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 26 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2653
- end exclusive
- true
- exact text
- treatment of metastatic NSCLC. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy. (1.7) Urothelial Carcinoma (UC) • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC. (1.8) • adult patients with unresectable or metastatic urothelial carcinoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2222
- current approval status
- not_reconciled
- duplicate text group
- dup-b15a6d7067569fc81a96
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-893511f1a741f5922e48
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2453
- end exclusive
- true
- exact text
- (1.7) Urothelial Carcinoma (UC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2422
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 27 · risk or warning
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- risk_or_warning_words_without_positive_predicate
- clinical review status
- pending
- content role
- risk_or_warning
- context span
- end
- 2777
- end exclusive
- true
- exact text
- Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy. (1.7) Urothelial Carcinoma (UC) • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC. (1.8) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.8) • adult patients with locally advanced or met
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2254
- current approval status
- not_reconciled
- duplicate text group
- dup-4b959cf30f555bdec493
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-522f5ef45788aa2ed347
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing
- kind
- age
- polarity
- not_inferred
- span
- end
- 2492
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2478
- context exact
- • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radica
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2499
- end exclusive
- true
- exact text
- adjuvant treatment of adult patients with U
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2456
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2577
- end exclusive
- true
- exact text
- • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2454
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 28 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2783
- end exclusive
- true
- exact text
- ssion on or after a platinum-based therapy. (1.7) Urothelial Carcinoma (UC) • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC. (1.8) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.8) • adult patients with locally advanced or metastati
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2378
- current approval status
- not_reconciled
- duplicate text group
- dup-4494eb43107da902255a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-3e56f1b09a58c285e396
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2583
- end exclusive
- true
- exact text
- (1.8)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2578
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 29 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2925
- end exclusive
- true
- exact text
- on or after a platinum-based therapy. (1.7) Urothelial Carcinoma (UC) • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC. (1.8) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.8) • adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoa
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2384
- current approval status
- not_reconciled
- duplicate text group
- dup-69311138eb8b05dbe31f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-5c87d4552809db858fa3
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with unresectable or metastatic urothelial carcinoma, as fi
- kind
- age
- polarity
- not_inferred
- span
- end
- 2600
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2586
- context exact
- • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2653
- end exclusive
- true
- exact text
- metastatic urothelial carcinoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2622
- context exact
- • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2653
- end exclusive
- true
- exact text
- unresectable or metastatic urothelial carcinoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2606
- context exact
- ts with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 2724
- end exclusive
- true
- exact text
- first-line treatment in combination with cisplatin and gemcitabine
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2658
- context exact
- or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 2724
- end exclusive
- true
- exact text
- in combination with cisplatin and gemcitabine
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2679
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2725
- end exclusive
- true
- exact text
- • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2584
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 30 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2931
- end exclusive
- true
- exact text
- ecurrence after undergoing radical resection of UC. (1.8) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.8) • adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvan
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2526
- current approval status
- not_reconciled
- duplicate text group
- dup-4494eb43107da902255a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-952f0346cda6e9ca4167
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2731
- end exclusive
- true
- exact text
- (1.8)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2726
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 31 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 2992
- end exclusive
- true
- exact text
- nce after undergoing radical resection of UC. (1.8) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.8) • adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2532
- current approval status
- not_reconciled
- duplicate text group
- dup-b8bf79a438aef3d16d08
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-9732c3e65dfbbd03afce
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with locally advanced or metastatic UC who:
- kind
- age
- polarity
- not_inferred
- span
- end
- 2748
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2734
- context exact
- • adult patients with locally advanced or metastatic UC who:
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 2792
- end exclusive
- true
- exact text
- metastatic UC who:
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2774
- context exact
- • adult patients with locally advanced or metastatic UC who:
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2792
- end exclusive
- true
- exact text
- locally advanced or metastatic UC who:
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2754
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2792
- end exclusive
- true
- exact text
- • adult patients with locally advanced or metastatic UC who:
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2732
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 32 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3073
- end exclusive
- true
- exact text
- atients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.8) • adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.8) Colorectal Cancer (CRC) • adult and pediatric (12 years and older who wei
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2593
- current approval status
- not_reconciled
- duplicate text group
- dup-806249522cfecd1c6031
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-0ffa99d8391076435058
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2873
- end exclusive
- true
- exact text
- • have disease progression during or following platinum-containing chemotherapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2793
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 33 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3193
- end exclusive
- true
- exact text
- ment in combination with cisplatin and gemcitabine. (1.8) • adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.8) Colorectal Cancer (CRC) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2674
- current approval status
- not_reconciled
- duplicate text group
- dup-2db520da2878acebf9fe
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-1f64625666ce55c2005f
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 2967
- end exclusive
- true
- exact text
- neoadjuvant or adjuvant treatment with platinu
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2921
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 2993
- end exclusive
- true
- exact text
- • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2874
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 34 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3223
- end exclusive
- true
- exact text
- have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.8) Colorectal Cancer (CRC) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal c
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2794
- current approval status
- not_reconciled
- duplicate text group
- dup-40c4562b047432cea241
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-316a05b4de7e12ce230f
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 3023
- end exclusive
- true
- exact text
- (1.8) Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2994
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 35 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3510
- end exclusive
- true
- exact text
- ng or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.8) Colorectal Cancer (CRC) • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), following combination treatment with intravenous nivolumab and ipilimumab. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. • adult and pediatric (12 years and older
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 2824
- current approval status
- not_reconciled
- duplicate text group
- dup-94b76454338b36837e6c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-b1cd364d16ec4f645349
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult and pediatric (12 years and older who weigh 30 kg or greate
- kind
- age
- polarity
- not_inferred
- span
- end
- 3031
- end exclusive
- true
- exact text
- adult
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3026
- context exact
- • adult and pediatric (12 years and older who weigh 30 kg or greater) patients wi
- kind
- age
- polarity
- not_inferred
- span
- end
- 3045
- end exclusive
- true
- exact text
- pediatric
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3036
- context exact
- • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or m
- kind
- age
- polarity
- not_inferred
- span
- end
- 3065
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3047
- context exact
- r who weigh 30 kg or greater) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cance
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3167
- end exclusive
- true
- exact text
- metastatic microsatellite instability-high
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3124
- context exact
- unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), following combination treatment with
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3213
- end exclusive
- true
- exact text
- MSI-H) or mismatch repair deficient (dMMR) co
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3168
- context exact
- 2 years and older who weigh 30 kg or greater) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colo
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3155
- end exclusive
- true
- exact text
- unresectable or metastatic microsatellite insta
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3108
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 3310
- end exclusive
- true
- exact text
- • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), following combination treatment with intravenous nivolumab and ipilimumab.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3024
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 36 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3516
- end exclusive
- true
- exact text
- esectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), following combination treatment with intravenous nivolumab and ipilimumab. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. • adult and pediatric (12 years and older who w
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3111
- current approval status
- not_reconciled
- duplicate text group
- dup-3866a1b82f68a487ef51
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-53506b8071b87e7c7a69
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 3316
- end exclusive
- true
- exact text
- (1.9)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3311
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 37 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 3668
- end exclusive
- true
- exact text
- ble or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), following combination treatment with intravenous nivolumab and ipilimumab. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irin
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3117
- current approval status
- not_reconciled
- duplicate text group
- dup-7d141ac9e4ee95da9c7a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-a7413e16a3f65e9c3521
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- nation with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3467
- end exclusive
- true
- exact text
- metastatic MSI-H or dMMR CRC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3439
- context exact
- dicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3467
- end exclusive
- true
- exact text
- unresectable or metastatic MSI-H or dMMR CRC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3423
- context exact
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 3467
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3371
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 3468
- end exclusive
- true
- exact text
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3317
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 38 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3875
- end exclusive
- true
- exact text
- ith intravenous nivolumab and ipilimumab. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. Hepatocellular Carcinoma (HCC) • adult pa
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3269
- current approval status
- not_reconciled
- duplicate text group
- dup-4ab309f5594e31ce8cda
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-5f2d00c07cbda82ffd11
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult and pediatric (12 years and older who weigh 30 kg or greate
- kind
- age
- polarity
- not_inferred
- span
- end
- 3476
- end exclusive
- true
- exact text
- adult
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3471
- context exact
- • adult and pediatric (12 years and older who weigh 30 kg or greater) patients wi
- kind
- age
- polarity
- not_inferred
- span
- end
- 3490
- end exclusive
- true
- exact text
- pediatric
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3481
- context exact
- • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with MSI-H or dMMR met
- kind
- age
- polarity
- not_inferred
- span
- end
- 3510
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3492
- context exact
- 2 years and older who weigh 30 kg or greater) patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3598
- end exclusive
- true
- exact text
- MSI-H or dMMR metastatic CRC that has progres
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3553
- context exact
- der who weigh 30 kg or greater) patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotec
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3612
- end exclusive
- true
- exact text
- metastatic CRC that has progressed following
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3567
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 3675
- end exclusive
- true
- exact text
- • adult and pediatric (12 years and older who weigh 30 kg or greater) patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3469
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 39 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 3881
- end exclusive
- true
- exact text
- and pediatric (12 years and older who weigh 30 kg or greater) patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. Hepatocellular Carcinoma (HCC) • adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3476
- current approval status
- not_reconciled
- duplicate text group
- dup-3866a1b82f68a487ef51
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-46053758caee9df2d5fc
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 3681
- end exclusive
- true
- exact text
- (1.9)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3676
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 40 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 4033
- end exclusive
- true
- exact text
- ediatric (12 years and older who weigh 30 kg or greater) patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • adul
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3482
- current approval status
- not_reconciled
- duplicate text group
- dup-7d141ac9e4ee95da9c7a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-d35ab492698b72791c43
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- nation with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3832
- end exclusive
- true
- exact text
- metastatic MSI-H or dMMR CRC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3804
- context exact
- dicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3832
- end exclusive
- true
- exact text
- unresectable or metastatic MSI-H or dMMR CRC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3788
- context exact
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 3832
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3736
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 3833
- end exclusive
- true
- exact text
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3682
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 41 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4064
- end exclusive
- true
- exact text
- opyrimidine, oxaliplatin, and irinotecan. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • adult patients with unresectable or
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3634
- current approval status
- not_reconciled
- duplicate text group
- dup-798303fc98e2731df5c2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-b69bbf4cca3737fb8ea5
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 3864
- end exclusive
- true
- exact text
- Hepatocellular Carcinoma (HCC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3834
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 42 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4219
- end exclusive
- true
- exact text
- rinotecan. (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • adult patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • Limit
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3665
- current approval status
- not_reconciled
- duplicate text group
- dup-4a441fef95cdbd30a5a7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-06fd8bf0b1f996b645a7
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with unresectable or metastatic HCC, as a first-line treatm
- kind
- age
- polarity
- not_inferred
- span
- end
- 3881
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3867
- context exact
- • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 3917
- end exclusive
- true
- exact text
- metastatic HCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3903
- context exact
- • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 3917
- end exclusive
- true
- exact text
- unresectable or metastatic HCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3887
- context exact
- • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 4018
- end exclusive
- true
- exact text
- first-line treatment following combination treatment with intravenous nivolumab and ipilimumab
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3924
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 4019
- end exclusive
- true
- exact text
- • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3865
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 43 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4226
- end exclusive
- true
- exact text
- or dMMR CRC. Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • adult patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • Limitations
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3820
- current approval status
- not_reconciled
- duplicate text group
- dup-9f89ae9f2570c0a8a2d2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-c2890a714949659a9a4c
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 4026
- end exclusive
- true
- exact text
- (1.10)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4020
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 44 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4404
- end exclusive
- true
- exact text
- R CRC. Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic HCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • adult patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic HCC. Esophageal Cancer • adult patients with completely res
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3827
- current approval status
- not_reconciled
- duplicate text group
- dup-f47111be1bb71799130b
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-87ee3eeaaffa10cc6f98
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with unresectable or metastatic HCC, who have been previous
- kind
- age
- polarity
- not_inferred
- span
- end
- 4043
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4029
- context exact
- • adult patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4079
- end exclusive
- true
- exact text
- metastatic HCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4065
- context exact
- • adult patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4079
- end exclusive
- true
- exact text
- unresectable or metastatic HCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4049
- context exact
- patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 4203
- end exclusive
- true
- exact text
- previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4095
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 4204
- end exclusive
- true
- exact text
- • adult patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4027
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 45 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4411
- end exclusive
- true
- exact text
- nd ipilimumab. (1.10) • adult patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic HCC. Esophageal Cancer • adult patients with completely resected e
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4005
- current approval status
- not_reconciled
- duplicate text group
- dup-9f89ae9f2570c0a8a2d2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-91912043e88b3115303c
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 4211
- end exclusive
- true
- exact text
- (1.10)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4205
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 46 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 4549
- end exclusive
- true
- exact text
- imumab. (1.10) • adult patients with unresectable or metastatic HCC, who have been previously treated with sorafenib, following combination treatment with intravenous nivolumab and ipilimumab. (1.10) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic HCC. Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4012
- current approval status
- not_reconciled
- duplicate text group
- dup-fb88529c1da036a3e0da
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-8b47b4150d2d6aef497a
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- nation with ipilimumab for the treatment of unresectable or metastatic HCC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4348
- end exclusive
- true
- exact text
- metastatic HCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4334
- context exact
- dicated in combination with ipilimumab for the treatment of unresectable or metastatic HCC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4348
- end exclusive
- true
- exact text
- unresectable or metastatic HCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4318
- context exact
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic HCC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 4348
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of unresectable or metastatic HCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4266
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 4349
- end exclusive
- true
- exact text
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic HCC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4212
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 47 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4567
- end exclusive
- true
- exact text
- n treatment with intravenous nivolumab and ipilimumab. (1.10) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic HCC. Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.11) • adult patien
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4150
- current approval status
- not_reconciled
- duplicate text group
- dup-94906f3d9d2dc37d8c6d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-2d8ae6eb167f713fff36
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 4367
- end exclusive
- true
- exact text
- Esophageal Cancer
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4350
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 48 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4745
- end exclusive
- true
- exact text
- ntravenous nivolumab and ipilimumab. (1.10) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic HCC. Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.11) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemot
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4168
- current approval status
- not_reconciled
- duplicate text group
- dup-7735eb8b87e6ad4bd3f6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-903cd7810f9334ba7d8c
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with completely resected esophageal or gastroesophageal jun
- kind
- age
- polarity
- not_inferred
- span
- end
- 4384
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4370
- context exact
- cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4544
- end exclusive
- true
- exact text
- neoadjuvant chemoradiotherapy (CRT)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4509
- context exact
- sophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 4544
- end exclusive
- true
- exact text
- who have received neoadjuvant chemoradiotherapy (CRT)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4491
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 4545
- end exclusive
- true
- exact text
- • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT).
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4368
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 49 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4752
- end exclusive
- true
- exact text
- CC. Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.11) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4346
- current approval status
- not_reconciled
- duplicate text group
- dup-44a193a6eb59fb6653a0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-1ef9af2420dafc62bc8b
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 4552
- end exclusive
- true
- exact text
- (1.11)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4546
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 50 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4984
- end exclusive
- true
- exact text
- phageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.11) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1). (1.11) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. • adult patients with unresect
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4353
- current approval status
- not_reconciled
- duplicate text group
- dup-b63d1505a162b0d13bfd
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-979f3103cd82858b4d87
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with unresectable advanced or metastatic esophageal squamou
- kind
- age
- polarity
- not_inferred
- span
- end
- 4569
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4555
- context exact
- • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoro
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4643
- end exclusive
- true
- exact text
- metastatic esophageal squamous cell carcino
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4600
- context exact
- - and platinum-containing chemotherapy whose tumors express PD-L1 (≥1).
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4783
- end exclusive
- true
- exact text
- PD-L1 (≥1)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4773
- context exact
- • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in co
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4622
- end exclusive
- true
- exact text
- unresectable advanced or metastatic esophageal
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4575
- context exact
- or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 4783
- end exclusive
- true
- exact text
- first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4656
- context exact
- geal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 4783
- end exclusive
- true
- exact text
- in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4677
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 4784
- end exclusive
- true
- exact text
- • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1).
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4553
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 51 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 4991
- end exclusive
- true
- exact text
- le advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1). (1.11) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. • adult patients with unresectable ad
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4585
- current approval status
- not_reconciled
- duplicate text group
- dup-44a193a6eb59fb6653a0
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-0cecc5f7adefd705e4f2
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 4791
- end exclusive
- true
- exact text
- (1.11)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4785
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 52 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 5153
- end exclusive
- true
- exact text
- nced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1). (1.11) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. (1.11) Gastric Cancer, Gastroesophageal Junction Cancer, and E
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4592
- current approval status
- not_reconciled
- duplicate text group
- dup-9766147085df91ab073f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-452963e952e66c8cdd6d
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- for the treatment of patients with unresectable advanced or metastatic ESCC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 4952
- end exclusive
- true
- exact text
- metastatic ESCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4937
- context exact
- bination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4952
- end exclusive
- true
- exact text
- unresectable advanced or metastatic ESCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4912
- context exact
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 4952
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4846
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 4953
- end exclusive
- true
- exact text
- • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4792
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 53 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5290
- end exclusive
- true
- exact text
- ose tumors express PD-L1 (≥1). (1.11) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. (1.11) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal ad
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4754
- current approval status
- not_reconciled
- duplicate text group
- dup-e951f385f03d636c4edb
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-4a4d97bc9da58c083672
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with unresectable advanced, recurrent or metastatic ESCC af
- kind
- age
- polarity
- not_inferred
- span
- end
- 4970
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4956
- context exact
- • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5055
- end exclusive
- true
- exact text
- metastatic ESCC after prior fluoropyrimidin
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5012
- context exact
- • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine-
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 4997
- end exclusive
- true
- exact text
- unresectable advanced
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4976
- context exact
- • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5043
- end exclusive
- true
- exact text
- recurrent or metastatic ESCC after prior flu
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4999
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 5090
- end exclusive
- true
- exact text
- • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4954
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 54 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5377
- end exclusive
- true
- exact text
- ent of patients with unresectable advanced or metastatic ESCC. • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. (1.11) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4891
- current approval status
- not_reconciled
- duplicate text group
- dup-12699266d2ad74e529c4
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-1048a4aada9e42e1a300
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 5177
- end exclusive
- true
- exact text
- (1.11) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5091
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 55 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5610
- end exclusive
- true
- exact text
- resectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. (1.11) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.12) 1.1 Advanced Renal Cell Carcinoma OPDIVO QVANTIG™, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 4978
- current approval status
- not_reconciled
- duplicate text group
- dup-5159f4a15a75b58950f2
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-743f813067e3cd77f27f
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • adult patients with advanced or metastatic gastric cancer, gastroesophagea
- kind
- age
- polarity
- not_inferred
- span
- end
- 5194
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5180
- context exact
- • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarc
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5237
- end exclusive
- true
- exact text
- metastatic gastric cancer
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5212
- context exact
- cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 5369
- end exclusive
- true
- exact text
- PD-L1 (≥1) in combination with fluoropyrimidi
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5324
- context exact
- • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarc
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5237
- end exclusive
- true
- exact text
- advanced or metastatic gastric cancer
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5200
- context exact
- d esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 5409
- end exclusive
- true
- exact text
- in combination with fluoropyrimidine- and platinum-containing chemotherapy
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5335
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 5410
- end exclusive
- true
- exact text
- • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5178
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 56 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 5617
- end exclusive
- true
- exact text
- metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.12) 1.1 Advanced Renal Cell Carcinoma OPDIVO QVANTIG™, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) follo
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5211
- current approval status
- not_reconciled
- duplicate text group
- dup-137ae652fcd71d78d864
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-0c98eb03a960dc9ed29b
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 5417
- end exclusive
- true
- exact text
- (1.12)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5411
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 57 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 5894
- end exclusive
- true
- exact text
- atic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.12) 1.1 Advanced Renal Cell Carcinoma OPDIVO QVANTIG™, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab combination therapy. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. OPDIVO QVANTIG, in combination with cabozantinib, is indicated for the fi
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5218
- current approval status
- not_reconciled
- duplicate text group
- dup-54e0be2fc605a6d3ba92
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-b14850e38f4974cb0e2c
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 5497
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5485
- qualifier mentions
- context exact
- s monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinom
- kind
- age
- polarity
- not_inferred
- span
- end
- 5544
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5530
- context exact
- 1.1 Advanced Renal Cell Carcinoma OPDIVO QVANTIG™, as monotherapy, is indicated for the first-line treatmen
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5465
- end exclusive
- true
- exact text
- Advanced Renal Cell Carcinoma OPDIVO QVANTI
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5422
- context exact
- treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab combi
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5619
- end exclusive
- true
- exact text
- advanced renal cell carcinoma (RCC) followi
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5576
- context exact
- inoma OPDIVO QVANTIG™, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab combination therapy.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 5676
- end exclusive
- true
- exact text
- first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab co
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5506
- context exact
- 1.1 Advanced Renal Cell Carcinoma OPDIVO QVANTIG™, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab combination therapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 5643
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intrav
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5469
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 5694
- end exclusive
- true
- exact text
- 1.1 Advanced Renal Cell Carcinoma OPDIVO QVANTIG™, as monotherapy, is indicated for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab combination therapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5418
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 58 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 6020
- end exclusive
- true
- exact text
- ed for the first-line treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma (RCC) following treatment with intravenous nivolumab and ipilimumab combination therapy. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. OPDIVO QVANTIG, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adul
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5495
- current approval status
- not_reconciled
- duplicate text group
- dup-d87ddbb0655b518e27e3
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-bd64e1db48b4db4419fd
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 5819
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of renal cell carcinoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5747
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 5820
- end exclusive
- true
- exact text
- Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5695
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 59 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 6149
- end exclusive
- true
- exact text
- treatment with intravenous nivolumab and ipilimumab combination therapy. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. OPDIVO QVANTIG, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic therapy. 1.2 Unresectable or Metastatic Melanoma OPDIVO QVAN
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5621
- current approval status
- not_reconciled
- duplicate text group
- dup-b71788ae717c122f5de1
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-86c9c8f6be874d662160
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 5883
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5871
- qualifier mentions
- context exact
- cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC.
- kind
- age
- polarity
- not_inferred
- span
- end
- 5930
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5916
- context exact
- dicated for the first-line treatment of adult patients with advanced RCC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 5948
- end exclusive
- true
- exact text
- advanced RCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5936
- context exact
- TIG, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 5948
- end exclusive
- true
- exact text
- first-line treatment of adult patients with advanced RCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5892
- context exact
- OPDIVO QVANTIG, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 5948
- end exclusive
- true
- exact text
- in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5837
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 5949
- end exclusive
- true
- exact text
- OPDIVO QVANTIG, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5821
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 60 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 6297
- end exclusive
- true
- exact text
- combination with ipilimumab for the treatment of renal cell carcinoma. OPDIVO QVANTIG, in combination with cabozantinib, is indicated for the first-line treatment of adult patients with advanced RCC. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic therapy. 1.2 Unresectable or Metastatic Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5750
- current approval status
- not_reconciled
- duplicate text group
- dup-f50da1a0149865393011
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-b20671b2d36e7f525685
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 5994
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5982
- qualifier mentions
- context exact
- QVANTIG, as monotherapy, is indicated for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic t
- kind
- age
- polarity
- not_inferred
- span
- end
- 6030
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6016
- context exact
- rapy, is indicated for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic therapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6079
- end exclusive
- true
- exact text
- advanced RCC who have received prior anti-a
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6036
- context exact
- cated for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic therapy.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 6096
- end exclusive
- true
- exact text
- who have received prior anti-angiogenic therapy
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6049
- context exact
- OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic therapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 6096
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic therapy
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5966
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 6097
- end exclusive
- true
- exact text
- OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic therapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5950
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 61 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 6520
- end exclusive
- true
- exact text
- line treatment of adult patients with advanced RCC. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with advanced RCC who have received prior anti-angiogenic therapy. 1.2 Unresectable or Metastatic Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma following treatme
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 5898
- current approval status
- not_reconciled
- duplicate text group
- dup-5100c753808d003f6bb6
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-3ad562a222e09d6b11b7
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 6182
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6170
- qualifier mentions
- context exact
- QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg o
- kind
- age
- polarity
- not_inferred
- span
- end
- 6209
- end exclusive
- true
- exact text
- adult
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6204
- context exact
- as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresect
- kind
- age
- polarity
- not_inferred
- span
- end
- 6232
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6214
- context exact
- indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic
- kind
- age
- polarity
- not_inferred
- span
- end
- 6251
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6233
- context exact
- 1.2 Unresectable or Metastatic Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult an
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6152
- end exclusive
- true
- exact text
- Metastatic Melanoma OPDIVO QVANTIG
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6118
- context exact
- s and older who weigh 30 kg or greater with unresectable or metastatic melanoma.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6319
- end exclusive
- true
- exact text
- metastatic melanoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6300
- context exact
- 1.2 Unresectable or Metastatic Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6149
- end exclusive
- true
- exact text
- Unresectable or Metastatic Melanoma OPDIVO QVAN
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6102
- context exact
- patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6319
- end exclusive
- true
- exact text
- unresectable or metastatic melanoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6284
- context exact
- 1.2 Unresectable or Metastatic Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 6319
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6154
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 6320
- end exclusive
- true
- exact text
- 1.2 Unresectable or Metastatic Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6098
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 62 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 6785
- end exclusive
- true
- exact text
- astatic Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma following treatment with intravenous nivolumab and ipilimumab combination therapy. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. 1.3 Adjuvant Treatment of Melanoma OPDIVO QVANTIG, as mono
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6121
- current approval status
- not_reconciled
- duplicate text group
- dup-4aa2d54d6003c8aca468
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-7678d6b6c7460f8e5b48
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 6365
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6353
- qualifier mentions
- context exact
- QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg o
- kind
- age
- polarity
- not_inferred
- span
- end
- 6392
- end exclusive
- true
- exact text
- adult
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6387
- context exact
- as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresect
- kind
- age
- polarity
- not_inferred
- span
- end
- 6415
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6397
- context exact
- indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic
- kind
- age
- polarity
- not_inferred
- span
- end
- 6434
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6416
- context exact
- s and older who weigh 30 kg or greater with unresectable or metastatic melanoma following treatment with intravenous nivolumab and ipilimumab combination therapy.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6526
- end exclusive
- true
- exact text
- metastatic melanoma following treatment wit
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6483
- context exact
- patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma following treatment with intravenous nivolumab and ipilimumab combinati
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6514
- end exclusive
- true
- exact text
- unresectable or metastatic melanoma following t
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6467
- context exact
- OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma following treatment with intravenous nivolumab and ipilimumab combin
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 6511
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma followin
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6337
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 6585
- end exclusive
- true
- exact text
- OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma following treatment with intravenous nivolumab and ipilimumab combination therapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6321
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 63 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 6926
- end exclusive
- true
- exact text
- adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic melanoma following treatment with intravenous nivolumab and ipilimumab combination therapy. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. 1.3 Adjuvant Treatment of Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with completel
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6386
- current approval status
- not_reconciled
- duplicate text group
- dup-5c506ca5c80f49026c53
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-d5619431e155b34c8167
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- nation with ipilimumab for the treatment of unresectable or metastatic melanoma.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 6725
- end exclusive
- true
- exact text
- metastatic melanoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6706
- context exact
- dicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6725
- end exclusive
- true
- exact text
- unresectable or metastatic melanoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6690
- context exact
- Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 6725
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of unresectable or metastatic melanoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6638
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 6726
- end exclusive
- true
- exact text
- Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6586
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 64 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 7191
- end exclusive
- true
- exact text
- intravenous nivolumab and ipilimumab combination therapy. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. 1.3 Adjuvant Treatment of Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. 1.4 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with rese
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6527
- current approval status
- not_reconciled
- duplicate text group
- dup-2d4ee94508e44d7b752d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-74260996cfe8ace7f0c0
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 6806
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6794
- qualifier mentions
- context exact
- as monotherapy, is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg o
- kind
- age
- polarity
- not_inferred
- span
- end
- 6842
- end exclusive
- true
- exact text
- adult
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6837
- context exact
- erapy, is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with complete
- kind
- age
- polarity
- not_inferred
- span
- end
- 6865
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6847
- context exact
- for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with completely resected Stage I
- kind
- age
- polarity
- not_inferred
- span
- end
- 6884
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6866
- context exact
- 1.3 Adjuvant Treatment of Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6774
- end exclusive
- true
- exact text
- Adjuvant Treatment of Melanoma OPDIVO QVANT
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6731
- context exact
- lanoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with c
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 6858
- end exclusive
- true
- exact text
- adjuvant treatment of adult and pediatric p
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6815
- context exact
- 1.3 Adjuvant Treatment of Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 6952
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with completely resected Stage IIB, Stag
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6778
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 6991
- end exclusive
- true
- exact text
- 1.3 Adjuvant Treatment of Melanoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6727
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 65 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 7465
- end exclusive
- true
- exact text
- , is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. 1.4 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC). 1.5 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6792
- current approval status
- not_reconciled
- duplicate text group
- dup-c6f61ee4c56ea87541d5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-21b769135656ab8cabdf
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 7138
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7126
- qualifier mentions
- context exact
- blet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small c
- kind
- age
- polarity
- not_inferred
- span
- end
- 7181
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7167
- context exact
- 1.4 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinu
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7042
- end exclusive
- true
- exact text
- Neoadjuvant Treatment of Resectable Non-Small
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6996
- context exact
- ination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lun
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7188
- end exclusive
- true
- exact text
- neoadjuvant treatment of adult patients with r
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7142
- context exact
- nt of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7254
- end exclusive
- true
- exact text
- in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung canc
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7075
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 7265
- end exclusive
- true
- exact text
- 1.4 Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC).
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 6992
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 66 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 7934
- end exclusive
- true
- exact text
- QVANTIG, in combination with platinum-doublet chemotherapy, is indicated as neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer (NSCLC). 1.5 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by OPDIVO QVANTIG as monotherapy in the adjuvant setting after surgical resection. 1.6 Metastatic Non-Small Cell Lung Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or af
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7066
- current approval status
- not_reconciled
- duplicate text group
- dup-7ab128ac47469b363579
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-5747c12e74e93291d30e
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 7425
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7413
- qualifier mentions
- context exact
- chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and n
- kind
- age
- polarity
- not_inferred
- span
- end
- 7473
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7459
- context exact
- itive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by OPDIVO QVANTIG as monoth
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7619
- end exclusive
- true
- exact text
- EGFR) mutations or anaplastic lymphoma kinas
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7575
- context exact
- or receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by OPDIVO QVANTIG as monotherapy in the adjuvant
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7641
- end exclusive
- true
- exact text
- ALK) rearrangements
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7622
- context exact
- 1.5 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7316
- end exclusive
- true
- exact text
- Neoadjuvant and Adjuvant Treatment of Resectab
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7270
- context exact
- on with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7480
- end exclusive
- true
- exact text
- neoadjuvant treatment of adult patients with r
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7434
- context exact
- angements, followed by OPDIVO QVANTIG as monotherapy in the adjuvant setting after surgical resection.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7733
- end exclusive
- true
- exact text
- adjuvant setting after surgical resection
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7692
- context exact
- nt of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplas
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7541
- end exclusive
- true
- exact text
- in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7362
- context exact
- oma kinase (ALK) rearrangements, followed by OPDIVO QVANTIG as monotherapy in the adjuvant setting after surgical resection.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7733
- end exclusive
- true
- exact text
- as monotherapy in the adjuvant setting after surgical resection
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7670
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 7734
- end exclusive
- true
- exact text
- 1.5 Neoadjuvant and Adjuvant Treatment of Resectable Non-Small Cell Lung Cancer OPDIVO QVANTIG, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by OPDIVO QVANTIG as monotherapy in the adjuvant setting after surgical resection.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7266
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 67 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 8166
- end exclusive
- true
- exact text
- known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, followed by OPDIVO QVANTIG as monotherapy in the adjuvant setting after surgical resection. 1.6 Metastatic Non-Small Cell Lung Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. Limitations of Use: OPDIVO QVANTIG
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7535
- current approval status
- not_reconciled
- duplicate text group
- dup-08f1c77db3904435a423
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-c32f30bbb8d03f3339ec
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 7821
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7809
- qualifier mentions
- context exact
- QVANTIG, as monotherapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with pro
- kind
- age
- polarity
- not_inferred
- span
- end
- 7857
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7843
- context exact
- 1.6 Metastatic Non-Small Cell Lung Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7782
- end exclusive
- true
- exact text
- Metastatic Non-Small Cell Lung Cancer OPDIV
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7739
- context exact
- rapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 7906
- end exclusive
- true
- exact text
- metastatic non-small cell lung cancer (NSCL
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7863
- context exact
- 1.6 Metastatic Non-Small Cell Lung Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of a
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7784
- end exclusive
- true
- exact text
- Metastatic Non-Small Cell Lung Cancer OPDIVO
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7739
- context exact
- rapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 7908
- end exclusive
- true
- exact text
- metastatic non-small cell lung cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7863
- context exact
- 1.6 Metastatic Non-Small Cell Lung Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 7965
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7793
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 7966
- end exclusive
- true
- exact text
- 1.6 Metastatic Non-Small Cell Lung Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7735
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 68 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 8331
- end exclusive
- true
- exact text
- ng Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. 1.7 Squamous Cell Carcinoma of the Head and Neck OPDIVO QVANTIG, as monothera
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7767
- current approval status
- not_reconciled
- duplicate text group
- dup-99e1775eef5cf1b0a61a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-f33b3126174141950e79
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 8025
- end exclusive
- true
- exact text
- EGFR or ALK genomic tumor aberrations should
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7981
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 8131
- end exclusive
- true
- exact text
- Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7967
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 69 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 8453
- end exclusive
- true
- exact text
- after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. 1.7 Squamous Cell Carcinoma of the Head and Neck OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 7932
- current approval status
- not_reconciled
- duplicate text group
- dup-452be74663a62268b5ca
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-d1c7e7105d840dcd93a9
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- dicated in combination with ipilimumab for the treatment of metastatic NSCLC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 8252
- end exclusive
- true
- exact text
- metastatic NSCLC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8236
- context exact
- dicated in combination with ipilimumab for the treatment of metastatic NSCLC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8252
- end exclusive
- true
- exact text
- metastatic NSCLC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8236
- context exact
- Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 8252
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of metastatic NSCLC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8184
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 8253
- end exclusive
- true
- exact text
- Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8132
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 70 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 8726
- end exclusive
- true
- exact text
- FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. 1.7 Squamous Cell Carcinoma of the Head and Neck OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy. 1.8 Urothelial Carcinoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing r
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8054
- current approval status
- not_reconciled
- duplicate text group
- dup-55abc92a873e1be833e1
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-2fb6aba24c4ec56f3530
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 8347
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8335
- qualifier mentions
- context exact
- QVANTIG, as monotherapy, is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the
- kind
- age
- polarity
- not_inferred
- span
- end
- 8383
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8369
- context exact
- cated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after pl
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 8445
- end exclusive
- true
- exact text
- metastatic squamous cell carcinoma of the h
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8402
- context exact
- rapy, is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8433
- end exclusive
- true
- exact text
- recurrent or metastatic squamous cell carcin
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8389
- context exact
- quamous Cell Carcinoma of the Head and Neck OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 8493
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8319
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 8526
- end exclusive
- true
- exact text
- 1.7 Squamous Cell Carcinoma of the Head and Neck OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8254
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 71 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- positive_statement_also_contains_qualification_review_required
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 8949
- end exclusive
- true
- exact text
- herapy, is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after platinum-based therapy. 1.8 Urothelial Carcinoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. OPDIVO QVANTIG, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic UC. OPDIVO QVANTIG, as monotherapy, is indic
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8327
- current approval status
- not_reconciled
- duplicate text group
- dup-ee9da724d3dcd26d5be7
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-f89f9386d8fe71d4e71f
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 8596
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8584
- qualifier mentions
- context exact
- as monotherapy, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recu
- kind
- age
- polarity
- not_inferred
- span
- end
- 8641
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8627
- context exact
- cinoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8648
- end exclusive
- true
- exact text
- adjuvant treatment of adult patients with u
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8605
- context exact
- 1.8 Urothelial Carcinoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 8742
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8568
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 8749
- end exclusive
- true
- exact text
- 1.8 Urothelial Carcinoma OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8527
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 72 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 9108
- end exclusive
- true
- exact text
- a OPDIVO QVANTIG, as monotherapy, is indicated for the adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. OPDIVO QVANTIG, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic UC. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemoth
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8550
- current approval status
- not_reconciled
- duplicate text group
- dup-86b82e5af103e4cf898c
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-a3fd83afc0486915248a
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 8825
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8813
- qualifier mentions
- context exact
- d gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic UC.
- kind
- age
- polarity
- not_inferred
- span
- end
- 8872
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8858
- context exact
- first-line treatment of adult patients with unresectable or metastatic UC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 8907
- end exclusive
- true
- exact text
- metastatic UC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8894
- context exact
- dicated for the first-line treatment of adult patients with unresectable or metastatic UC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 8907
- end exclusive
- true
- exact text
- unresectable or metastatic UC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8878
- context exact
- nation with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic UC.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 8907
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable or metastatic UC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8834
- context exact
- OPDIVO QVANTIG, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic UC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 8907
- end exclusive
- true
- exact text
- in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic UC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8766
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 8908
- end exclusive
- true
- exact text
- OPDIVO QVANTIG, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic UC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8750
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 73 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 9233
- end exclusive
- true
- exact text
- fter undergoing radical resection of UC. OPDIVO QVANTIG, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with unresectable or metastatic UC. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8709
- current approval status
- not_reconciled
- duplicate text group
- dup-981b89d250a3b97890e9
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-dda615189ec764d45288
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 8953
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8941
- qualifier mentions
- context exact
- QVANTIG, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic UC who:
- kind
- age
- polarity
- not_inferred
- span
- end
- 8989
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8975
- context exact
- or the treatment of adult patients with locally advanced or metastatic UC who:
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9033
- end exclusive
- true
- exact text
- metastatic UC who:
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9015
- context exact
- rapy, is indicated for the treatment of adult patients with locally advanced or metastatic UC who:
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9033
- end exclusive
- true
- exact text
- locally advanced or metastatic UC who:
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8995
- context exact
- OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic UC who:
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 9033
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic UC who:
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8925
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 9033
- end exclusive
- true
- exact text
- OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic UC who:
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8909
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 74 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 9314
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable or metastatic UC. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 1.9 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Col
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8834
- current approval status
- not_reconciled
- duplicate text group
- dup-806249522cfecd1c6031
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-8b79c7560f89ffb1a865
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 9114
- end exclusive
- true
- exact text
- • have disease progression during or following platinum-containing chemotherapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9034
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 75 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 9434
- end exclusive
- true
- exact text
- QVANTIG, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 1.9 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years a
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 8915
- current approval status
- not_reconciled
- duplicate text group
- dup-2db520da2878acebf9fe
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-196f82cc230c2f11441b
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9208
- end exclusive
- true
- exact text
- neoadjuvant or adjuvant treatment with platinu
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9162
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 9234
- end exclusive
- true
- exact text
- • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9115
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 76 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 9884
- end exclusive
- true
- exact text
- have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. 1.9 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) following treatment with intravenous nivolumab and ipilimumab combination therapy. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater, with MSI-H or dMMR metastatic CRC that has progressed fol
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9035
- current approval status
- not_reconciled
- duplicate text group
- dup-d3e29f6a9f648798526e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-90fe8130eb904f672463
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 9373
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9361
- qualifier mentions
- context exact
- QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg o
- kind
- age
- polarity
- not_inferred
- span
- end
- 9400
- end exclusive
- true
- exact text
- adult
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9395
- context exact
- as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresect
- kind
- age
- polarity
- not_inferred
- span
- end
- 9423
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9405
- context exact
- indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic
- kind
- age
- polarity
- not_inferred
- span
- end
- 9442
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9424
- context exact
- icrosatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult an
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9343
- end exclusive
- true
- exact text
- Metastatic Colorectal Cancer OPDIVO QVANTIG
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9300
- context exact
- s and older who weigh 30 kg or greater with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cance
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9534
- end exclusive
- true
- exact text
- metastatic microsatellite instability-high
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9491
- context exact
- unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) following treatment with intravenous n
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9580
- end exclusive
- true
- exact text
- MSI-H) or mismatch repair deficient (dMMR) co
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9535
- context exact
- icrosatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult an
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9343
- end exclusive
- true
- exact text
- Metastatic Colorectal Cancer OPDIVO QVANTIG
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9300
- context exact
- patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colo
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9522
- end exclusive
- true
- exact text
- unresectable or metastatic microsatellite insta
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9475
- context exact
- pair Deficient Metastatic Colorectal Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) c
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 9519
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic microsatellite in
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9345
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 9684
- end exclusive
- true
- exact text
- 1.9 Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) following treatment with intravenous nivolumab and ipilimumab combination therapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9235
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 77 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- source_defined_disease_abbreviation
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 10154
- end exclusive
- true
- exact text
- le or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) following treatment with intravenous nivolumab and ipilimumab combination therapy. OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater, with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. 1.10 Hepatocellular Carcinoma • OPDIVO QVANTIG, a
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9485
- current approval status
- not_reconciled
- duplicate text group
- dup-ae7ffdd999bb18d8139e
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-e4d180467623823129c2
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 9729
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9717
- qualifier mentions
- context exact
- QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg o
- kind
- age
- polarity
- not_inferred
- span
- end
- 9756
- end exclusive
- true
- exact text
- adult
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9751
- context exact
- as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater, with MSI-H o
- kind
- age
- polarity
- not_inferred
- span
- end
- 9779
- end exclusive
- true
- exact text
- pediatric patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9761
- context exact
- indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater, with MSI-H or dMMR metastatic C
- kind
- age
- polarity
- not_inferred
- span
- end
- 9798
- end exclusive
- true
- exact text
- 12 years and older
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9780
- context exact
- atients 12 years and older who weigh 30 kg or greater, with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 9877
- end exclusive
- true
- exact text
- MSI-H or dMMR metastatic CRC that has progres
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9832
- context exact
- rs and older who weigh 30 kg or greater, with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotec
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 9891
- end exclusive
- true
- exact text
- metastatic CRC that has progressed following
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9846
- context exact
- OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater, with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplat
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 9875
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater, with MSI-H or dMMR metastatic CRC that has progr
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9701
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 9954
- end exclusive
- true
- exact text
- OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult and pediatric patients 12 years and older who weigh 30 kg or greater, with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9685
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 78 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 10304
- end exclusive
- true
- exact text
- t and pediatric patients 12 years and older who weigh 30 kg or greater, with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. 1.10 Hepatocellular Carcinoma • OPDIVO QVANTIG, as monotherapy, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following tr
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9755
- current approval status
- not_reconciled
- duplicate text group
- dup-7d141ac9e4ee95da9c7a
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-091295c4421e3117861e
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- nation with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 10103
- end exclusive
- true
- exact text
- metastatic MSI-H or dMMR CRC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10075
- context exact
- dicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10103
- end exclusive
- true
- exact text
- unresectable or metastatic MSI-H or dMMR CRC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10059
- context exact
- Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 10103
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10007
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 10104
- end exclusive
- true
- exact text
- Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9955
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 79 · unclassified context
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- no_unambiguous_positive_indication_predicate
- clinical review status
- pending
- content role
- unclassified_context
- context span
- end
- 10334
- end exclusive
- true
- exact text
- a fluoropyrimidine, oxaliplatin, and irinotecan. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. 1.10 Hepatocellular Carcinoma • OPDIVO QVANTIG, as monotherapy, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following treatment with intravenous nivol
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9905
- current approval status
- not_reconciled
- duplicate text group
- dup-fbb9245bbf99b08578c5
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-71532156e8b8ead17e0e
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 10134
- end exclusive
- true
- exact text
- 1.10 Hepatocellular Carcinoma
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10105
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- unclear
Passage 80 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 10574
- end exclusive
- true
- exact text
- in, and irinotecan. Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic MSI-H or dMMR CRC. 1.10 Hepatocellular Carcinoma • OPDIVO QVANTIG, as monotherapy, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following treatment with intravenous nivolumab and ipilimumab combination therapy. • OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafenib follo
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 9935
- current approval status
- not_reconciled
- duplicate text group
- dup-4f55931832169494e1d1
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-a9fe855c03266c6053be
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 10181
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10169
- qualifier mentions
- context exact
- s monotherapy, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (H
- kind
- age
- polarity
- not_inferred
- span
- end
- 10228
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10214
- context exact
- first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following treatment with intravenous nivolumab and ipilimumab
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 10293
- end exclusive
- true
- exact text
- metastatic hepatocellular carcinoma (HCC) f
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10250
- context exact
- dicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following treatment with intravenous nivolumab an
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10281
- end exclusive
- true
- exact text
- unresectable or metastatic hepatocellular carci
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10234
- context exact
- • OPDIVO QVANTIG, as monotherapy, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following treatment with intravenous nivolumab and ipilimumab combination therapy.
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 10360
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following treatment with intravenous nivolumab and ipilimumab combin
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10190
- context exact
- • OPDIVO QVANTIG, as monotherapy, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following treatment with intravenous nivolumab and ipilimumab combination therapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 10327
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following treatment with intravenou
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10153
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 10374
- end exclusive
- true
- exact text
- • OPDIVO QVANTIG, as monotherapy, is indicated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following treatment with intravenous nivolumab and ipilimumab combination therapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10135
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 81 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 10852
- end exclusive
- true
- exact text
- icated for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) following treatment with intravenous nivolumab and ipilimumab combination therapy. • OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafenib following treatment with intravenous nivolumab and ipilimumab combination therapy . Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable or metastatic HCC. 1.11 Esophageal Cancer OPDIVO QVANTIG as monother
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10175
- current approval status
- not_reconciled
- duplicate text group
- dup-4c7ec743bfde9c2477bc
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-4813948361f0c5c56530
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 10421
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10409
- qualifier mentions
- context exact
- QVANTIG, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (H
- kind
- age
- polarity
- not_inferred
- span
- end
- 10457
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10443
- context exact
- ed for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafenib following tre
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 10522
- end exclusive
- true
- exact text
- metastatic hepatocellular carcinoma (HCC) w
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10479
- context exact
- rapy, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafenib f
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10510
- end exclusive
- true
- exact text
- unresectable or metastatic hepatocellular carci
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10463
- context exact
- or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafenib following treatment with intravenous nivolumab and ipilimumab combination therapy .
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 10651
- end exclusive
- true
- exact text
- previously treated with sorafenib following treatment with intravenous nivolumab and ipilimumab combination therapy
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10535
- context exact
- • OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafenib following treatment with intravenous nivolumab and ipilimu
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 10567
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafeni
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10393
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 10652
- end exclusive
- true
- exact text
- • OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafenib following treatment with intravenous nivolumab and ipilimumab combination therapy .
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10375
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 82 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 11002
- end exclusive
- true
- exact text
- ents with unresectable or metastatic hepatocellular carcinoma (HCC) who have been previously treated with sorafenib following treatment with intravenous nivolumab and ipilimumab combination therapy . Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable or metastatic HCC. 1.11 Esophageal Cancer OPDIVO QVANTIG as monotherapy, is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10453
- current approval status
- not_reconciled
- duplicate text group
- dup-046f6edb9235e4e7c57d
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-78209fbe77ae016ee74b
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- ilimumab for the treatment of patients with unresectable or metastatic HCC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 10801
- end exclusive
- true
- exact text
- metastatic HCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10787
- context exact
- bination with ipilimumab for the treatment of patients with unresectable or metastatic HCC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10801
- end exclusive
- true
- exact text
- unresectable or metastatic HCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10771
- context exact
- Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable or metastatic HCC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 10801
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of patients with unresectable or metastatic HCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10705
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 10802
- end exclusive
- true
- exact text
- Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable or metastatic HCC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10653
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 83 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 11272
- end exclusive
- true
- exact text
- us nivolumab and ipilimumab combination therapy . Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable or metastatic HCC. 1.11 Esophageal Cancer OPDIVO QVANTIG as monotherapy, is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT). OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esopha
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10603
- current approval status
- not_reconciled
- duplicate text group
- dup-4375c3171c4c035c2485
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-cf2bf456072f0374a8d5
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 10869
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10857
- qualifier mentions
- context exact
- phageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).
- kind
- age
- polarity
- not_inferred
- span
- end
- 11017
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11003
- context exact
- Cancer OPDIVO QVANTIG as monotherapy, is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 10921
- end exclusive
- true
- exact text
- adjuvant treatment of completely resected e
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10878
- context exact
- dual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11071
- end exclusive
- true
- exact text
- neoadjuvant chemoradiotherapy (CRT)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11036
- context exact
- n cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 11071
- end exclusive
- true
- exact text
- who have received neoadjuvant chemoradiotherapy (CRT)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11018
- context exact
- 1.11 Esophageal Cancer OPDIVO QVANTIG as monotherapy, is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 11015
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patien
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10841
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 11072
- end exclusive
- true
- exact text
- 1.11 Esophageal Cancer OPDIVO QVANTIG as monotherapy, is indicated for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT).
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10803
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 84 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 11580
- end exclusive
- true
- exact text
- the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in adult patients who have received neoadjuvant chemoradiotherapy (CRT). OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] . Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. OPDIVO QVANTIG as monotherapy, is indic
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 10873
- current approval status
- not_reconciled
- duplicate text group
- dup-7e5a27e534f63df1e87f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-c9f73ca71f80540e4d06
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 11177
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11165
- qualifier mentions
- context exact
- chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamou
- kind
- age
- polarity
- not_inferred
- span
- end
- 11224
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11210
- context exact
- e treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Ad
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11298
- end exclusive
- true
- exact text
- metastatic esophageal squamous cell carcino
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11255
- context exact
- phageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] .
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11373
- end exclusive
- true
- exact text
- PD-L1 (≥1) [see Dosage and Administration (2
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11329
- context exact
- dicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11277
- end exclusive
- true
- exact text
- unresectable advanced or metastatic esophageal
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11230
- context exact
- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] .
- kind
- prior_therapy_or_line
- polarity
- not_inferred
- span
- end
- 11356
- end exclusive
- true
- exact text
- first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11186
- context exact
- OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 11268
- end exclusive
- true
- exact text
- in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic es
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11089
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 11380
- end exclusive
- true
- exact text
- OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] .
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11073
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Passage 85 · limitation of use
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- negative_or_not_established_clause
- clinical review status
- pending
- content role
- limitation_of_use
- context span
- end
- 11740
- end exclusive
- true
- exact text
- the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] . Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. OPDIVO QVANTIG as monotherapy, is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11181
- current approval status
- not_reconciled
- duplicate text group
- dup-9766147085df91ab073f
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-ba2fa491a7f6792dcfc8
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- Source null
- qualifier mentions
- context exact
- for the treatment of patients with unresectable advanced or metastatic ESCC.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11539
- end exclusive
- true
- exact text
- metastatic ESCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11524
- context exact
- bination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11539
- end exclusive
- true
- exact text
- unresectable advanced or metastatic ESCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11499
- context exact
- Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 11539
- end exclusive
- true
- exact text
- in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11433
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 11540
- end exclusive
- true
- exact text
- Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11381
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- not_applicable
Passage 86 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- no_tumor_directed_keyword_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 11941
- end exclusive
- true
- exact text
- see Dosage and Administration (2.2) ] . Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. OPDIVO QVANTIG as monotherapy, is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. 1.12 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the t
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11341
- current approval status
- not_reconciled
- duplicate text group
- dup-5d7a2bce692d571f7acb
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-b7d31a5442d821914bdc
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 11584
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11572
- qualifier mentions
- context exact
- O QVANTIG as monotherapy, is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC a
- kind
- age
- polarity
- not_inferred
- span
- end
- 11620
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11606
- context exact
- of adult patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy.
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 11706
- end exclusive
- true
- exact text
- metastatic ESCC after prior fluoropyrimidin
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11663
- context exact
- rapy, is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11647
- end exclusive
- true
- exact text
- unresectable advanced
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11626
- context exact
- the treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and plati
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11658
- end exclusive
- true
- exact text
- recurrent
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11649
- context exact
- of adult patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy.
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 11708
- end exclusive
- true
- exact text
- metastatic ESCC after prior fluoropyrimidine-
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11663
- context exact
- OPDIVO QVANTIG as monotherapy, is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy.
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 11730
- end exclusive
- true
- exact text
- as monotherapy, is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based ch
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11556
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 11741
- end exclusive
- true
- exact text
- OPDIVO QVANTIG as monotherapy, is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy.
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11541
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- non_oncology_or_unclear_candidate
Passage 87 · positive indication candidate
- application numbers
- BLA761381
- brand names
- OPDIVO QVANTIG
- classification reasons
- explicit_positive_indication_predicate
- tumor_or_malignant_hematology_words_in_positive_statement
- clinical review status
- pending
- content role
- positive_indication_candidate
- context span
- end
- 12148
- end exclusive
- true
- exact text
- PDIVO QVANTIG as monotherapy, is indicated for the treatment of adult patients with unresectable advanced, recurrent, or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. 1.12 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] .
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11542
- current approval status
- not_reconciled
- duplicate text group
- dup-0e219da5cac0ef98ba33
- extraction review status
- automated_candidate_pending_source_review
- generic names
- NIVOLUMAB AND HYALURONIDASE-NVHY
- id
- ind-span-2a2cec0cfa782de9d98a
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- positive predicate support span
- end
- 11931
- end exclusive
- true
- exact text
- is indicated
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11919
- qualifier mentions
- context exact
- -containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophagea
- kind
- age
- polarity
- not_inferred
- span
- end
- 11967
- end exclusive
- true
- exact text
- adult patients
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11953
- context exact
- icated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarc
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 12010
- end exclusive
- true
- exact text
- metastatic gastric cancer
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11985
- context exact
- cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] .
- kind
- biomarker
- polarity
- not_inferred
- span
- end
- 12141
- end exclusive
- true
- exact text
- PD-L1 (≥1) [see Dosage and Administration (2
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 12097
- context exact
- rapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarc
- kind
- stage_or_setting
- polarity
- not_inferred
- span
- end
- 12010
- end exclusive
- true
- exact text
- advanced or metastatic gastric cancer
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11973
- context exact
- ction Cancer, and Esophageal Adenocarcinoma OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose
- kind
- regimen
- polarity
- not_inferred
- span
- end
- 12022
- end exclusive
- true
- exact text
- in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesop
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11843
- regulatory links
- schema version
- 0.1.0
- source batch sha256
- 0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07
- source defined aliases
- abbreviation
- NSCLC
- definition exact
- Non-Small Cell Lung Cancer
- definition span
- end
- 1424
- end exclusive
- true
- exact text
- Non-Small Cell Lung Cancer (NSCLC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 1390
- abbreviation
- CRC
- definition exact
- Colorectal Cancer
- definition span
- end
- 3023
- end exclusive
- true
- exact text
- Colorectal Cancer (CRC)
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 3000
- source span
- end
- 12148
- end exclusive
- true
- exact text
- 1.12 Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the treatment of adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) [see Dosage and Administration (2.2) ] .
- label id
- 1ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a
- offset unit
- unicode_code_points
- source array index
- 0
- source field
- indications_and_usage_exact
- source text sha256
- 2752de64f809563e0adb6a2f4f307e1f930b4fe55c5721c928890afcb9aff780
- start
- 11742
- source url
- https://api.fda.gov/drug/label.json?search=id%3A%221ce25608-1b8f-4d49-9ffd-6c8c61bf4f1a%22
- spl effective date
- 2026-05-12
- spl set id
- 7f8c38fa-42f4-4387-9e8c-7a1c66855d8b
- spl version
- 9
- structured fields status
- not_extracted_no_values_inferred_from_mentions
- structured indication
- age
- Source null
- approval pathway
- Source null
- biomarker and test
- Source null
- disease stage
- Source null
- limitations
- Source null
- line
- Source null
- prior therapy
- Source null
- regimen
- Source null
- tumor histology
- Source null
- use intent
- tumor_directed_candidate
Preserved source evidence · Not medical advice
Triangle